RecruitingNCT07582783

A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania

Persistence to Treatment With Guselkumab in Bio-Naive Patients With Moderate-to-Severe Plaque Psoriasis: A Romanian Non-Interventional Multi-center Observational Study

Sponsor

Janssen Research & Development, LLC

Enrollment

200 participants

Start Date

May 15, 2026

Study Type

OBSERVATIONAL

Conditions

Psoriasis

Summary

This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Has a confirmed diagnosis of moderate-to-severe plaque psoriasis
Participant must sign an informed consent form allowing source data verification in accordance with local requirements
Is able to read, understand, and complete the patient reported outcomes (PRO) instruments in local language and comply with completion of all PRO instruments
No previous exposure to biological treatment, including guselkumab (bio-naive patient)
Intended for the treatment with guselkumab according to the approved indication

Exclusion Criteria4

Meets any of the contraindications according to the latest version of the locally approved summary of product characteristics (SmPC)
Is pregnant or lactating
Current or recent (in the last 30 days prior to first SC dose of guselkumab) participation in any interventional study with investigational product.
Currently enrolled in another observational study sponsored or managed by a Johnson \& Johnson company

Interested in this trial?

Get notified about updates and connect with the research team.